Nagla Abdel Karim, MD
Medical Oncology · Fairfax, VANPI 1881805166
Payments from drug & device makers
Across 257 payments — averaging $3546.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$286K
- Incyte Corporation$130K
- E.r. Squibb & Sons, L.L.C.$81K
- Eli Lilly$58K
- Exelixis Inc.$53K
- Astrazeneca UK Limited$47K
- plus $257K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 7 | $285,805 |
| Incyte Corporation | 64 | $129,999 |
| E.r. Squibb & Sons, L.L.C. | 6 | $81,498 |
| Eli Lilly | 1 | $57,673 |
| Exelixis Inc. | 2 | $52,630 |
| Astrazeneca UK Limited | 21 | $46,735 |
| Regeneron Healthcare Solutions, Inc. | 43 | $43,252 |
| AstraZeneca | 19 | $40,632 |
| AbbVie | 14 | $37,399 |
| Bayer | 2 | $24,272 |
| GSK | 3 | $23,342 |
| Genentech, Inc. | 5 | $16,435 |
| Sanofi | 10 | $14,225 |
| Jazz Pharmaceuticals Inc. | 6 | $10,555 |
| Amgen | 7 | $9,758 |
| Genentech USA, Inc. | 9 | $7,392 |
| Novocure Inc. | 6 | $5,147 |
| Johnson & Johnson(2 entities) | 7 | $4,900 |
| Ipsen Biopharmaceuticals, Inc | 1 | $4,800 |
| Daiichi Sankyo Inc. | 3 | $3,875 |
| G1 Therapeutics, Inc. | 2 | $3,617 |
| Catalyst Pharmaceuticals, Inc. | 2 | $2,350 |
| Gilead | 3 | $2,335 |
| Boehringer Ingelheim | 2 | $1,612 |
| Coherus Oncology, Inc. | 3 | $359 |
| EUSA Pharma (US) LLC | 1 | $225 |
| Morphosys, US Inc. | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $120 |
| Dova Pharmaceuticals | 1 | $119 |
| Pharmacosmos Therapeutics Inc. | 1 | $88 |
| Caris MPI, Inc. | 1 | $36 |
| Boston Scientific | 1 | $19 |
| Epizyme, Inc. | 1 | $16 |
| Mirati Therapeutics, Inc. | 1 | $15 |
How this compares
$911,356 in reported general payments places this provider in the 80th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Fairfax
- Alexander SpiraFairfax$69.5M
- Kathleen HarndenFairfax$4M
- Adam CohenFairfax$2.2M
- Janakiraman SubramanianFairfax$1.9M
- Timothy CannonFairfax$1.9M
- Anne FavretFairfax$1.9M
- John DeekenFairfax$1.6M
- Arthur WinerFairfax$923K
- Amin BenyounesFairfax$824K
- Eun-Mi YuFairfax$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.